Generic Name and Formulations:
Mesalamine 250mg, 500mg; controlled-rel caps.
Shire US, Inc.
Indications for PENTASA:
Mildly-to-moderately active ulcerative colitis.
Swallow whole; may open caps and sprinkle entire contents onto applesauce or yogurt, consume immediately. 1g four times daily for up to 8 weeks.
Discontinue if acute intolerance syndrome is suspected. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Renal disease; monitor SCr, BUN, proteinuria. Hepatic impairment. Pregnancy (Cat.B). Nursing mothers.
May interfere with urinary normetanephrine test by liquid chromatography; consider alternative assay.
Diarrhea, headache, nausea, abdominal pain, dyspepsia, vomiting, rash; nephrotoxicity.
Caps 250mg—240; 500mg—120
Clinical Pain Advisor Articles
- Deaths After Nonfatal Opioid Overdose: Causes and Risk Factors
- Treatment for Opioid Use Disorder Associated With Reduced Risk for Opioid-Related Deaths
- Opioid-Free Analgesia Use for Postsurgical Pain Limited
- Clonidine May Not Improve Post-Cesarean Delivery Analgesia
- No Added Value With Liposomal Bupivacaine Following TKA With Peripheral Nerve Block
- Recommendations for Perioperative Pain Management in Patients With Opioid Tolerance
- Vertebroplasty Comparable With Placebo for Acute Vertebral Compression Fractures
- Capsaicin 8% Patch May Be Effective in Neuropathic Pain
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Prior Authorization Policy May Help Reduce Long-Acting Opioid Use
- Opioid-Related Deaths Represent Significant Public Health Burden
- Addressing Confidentiality Concerns With Electronic Access to Pediatric Medical Records
- Opioid-Related Adverse Events Common After Invasive Procedures
- Diagnosis and Treatment of Migraine in Children Should Consider Atopy
- Led by AG Sessions, DOJ Declines to Defend ACA Against Federal Lawsuit